Lung Cancer is complex and can seem overwhelming at times. Below are resources that we hope will help you make sense of it all. Research -Survivor Support- Advocacy.
SFAC is working to change attitudes and perceptions about lung cancer through inspiring survivor stories and a vibrant running community. No days off until we have a cure!
The more you know!
Resources and useful links
Links to helpful information and organizations
Lung Cancer 101 from our friends at LUNGevity Foundation. This guide helps understand how lung cancer develops, how it can be found and treatment options. https://lungevity.org/for-patients-caregivers/lung-cancer-101
Radon Test Kit ordering information. http://sosradon.org/test-kits
ALCF’s Patient Education Handbook – Navigating Lung Cancer: 360° of HOPE. This is the first-ever comprehensive, centralized, up-to-date patient resource exclusively devoted to lung cancer and vetted by experts in the field. It provides detailed information in laymen’s terms in an easy-to-read format. https://www.lungcancerfoundation.org/handbook/
The Lung Cancer Foundation has terrific resources for patients and caregivers. https://www.lungcancerfoundation.org/patients/
The National Comprehensive Cancer Network has resources that are fairly technical but are meant to help patients with cancer talk with their physicians about the best treatments options. https://www.nccn.org/patients/guidelines/cancers.aspx
Triage Cancer has a “Resources by Topic” page that is very helpful. https://triagecancer.org/resources-by-topic
LUNGevity’s Survivorship Conferences are a fantastic way to meet survivors, caregivers, advocates and medical professionals. Learn more here… https://lungevity.org/events/lungevitys-survivorship-conferences
We are constantly looking for the latest information to share. Please submit any articles or stories here.
1/03/2019 New England Journal of Medicine: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Summary: Supplementation with vitamin D did not result in a lower incidence of invasive cancer or cardiovascular events than placebo. (Funded by the National Institutes of Health and others; VITAL ClinicalTrials.gov number, NCT01169259.) Read the full article here.
12/13/2018 CURE (www.curetoday.com): Immunotherapy Side Effects May Be More Prevalent in Real World Than in Studies
Summary: Some side effects of immunotherapy could are under-reported when drugs are in clinical trials. Read the full article here.
12/13/2018 New England Journal of Medicine: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Summary: Durvalumab therapy resulted in significantly longer overall survival than placebo. No new safety signals were identified. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461.) Read the full article here.
12/06/2018 New England Journal of Medicine: First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Summary: The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by F. Hoffmann–La Roche/Genentech; IMpower133 ClinicalTrials.gov number, NCT02763579.) Read the full article here.
11/22/2018 New England Journal of Medicine: Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Summary: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435.) Read the full article here.
12/18/2018 CURE (www.curetoday.com): Billionaire Philanthropist Discusses His Institute’s Work to Perfect Cancer Immunotherapy
Summary: Interview with Sean Parker who was President of Facebook at age 24. Now, 15 years later, he has directed a portion of his social media wealth and a significant amount of his time and passion to the cause of fighting cancer through immunotherapy. Read the full article/interview here.
10/30/2018 CURE (www.curetoday.com): FDA Approves Keytruda Combination for Non-Small Cell Lung Cancer Subset
Summary: Merck’s Keytruda continues to win favor and extend lives. FDA grants broader use of the drug for NSCLC. Read the full article here.